SINGAPORE, July 21, 2026 /PRNewswire/ -- Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) across its Asia-Pacific markets. Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect that damages bone marrow, significantly impacting its hematopoietic function (or its ability to produce healthy blood cells). For patients with extensive-stage small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment, yet it is a major dose limiting co…READ FULL ARTICLE
